Background
The solid tumor microvasculature is characterized by structural and functional abnormality and mediates several deleterious aspects of tumor behavior. Here we determine the role of vascular endothelial protein tyrosine phosphatase (VE-PTP), which deactivates endothelial cell (EC) Tie-2 receptor tyrosine kinase, thereby impairing maturation of tumor vessels.
Unlike blood vessels in healthy tissue, the solid tumor microvasculature is dysfunctional and immature. Tumor vessels harbor structural and functional instability, which facilitates several distinct stages of tumor progression, including early sprouting angiogenesis, metastatic cell extravasation into distant organs, and the development of established tumor hypoxia, which fuels metastasis and impairs the efficacy of antitumor therapies (1) (2) (3) (4) (5) (6) (7) (8) (9) .
The endothelial cell (EC) receptor tyrosine kinase Tie-2/Tek is a critical regulator of vascular maturity. Tie-2 activation by its agonistic ligand angiopoietin 1 (Ang-1) increases perivascular cell (PVC) coverage, tightens EC junctions, reduces permeability, and increases vessel diameter (10) (11) (12) . Angiopoeitin-2 (Ang-2) antagonizes the effects of Ang-1 in a context-dependent manner (6) .
Recent studies have shown a deleterious role for Ang-2 in mediating tumor vessel abnormalities and metastasis (13, 14) , suggesting that Tie-2 deactivation by Ang-2 in part mediates the unstable vessel phenotype seen within tumors. Current strategies targeting the Ang/Tie-2 axis in tumors have focused primarily on direct targeting of the angiopoietins, but such studies have not directly examined complex context-dependent interactions between Ang-1 and Ang-2 or the effects of angiopoietin blockade on Tie-2 activity (15) (16) (17) (18) . There are currently 10 agents targeting the Ang/Tie-2 axis under investigation in clinical trials (19) .
Vascular endothelial protein tyrosine phosphatase (VE-PTP) is an EC-specific receptor tyrosine phosphatase that dephosphorylates and consequently inactivates Tie-2 (20) . The role of VE-PTP in the tumor vasculature is unknown. Recently, AKB-9778 has been developed as a novel, potent, and selective inhibitor of VE-PTP through structural modifications of 1,2,3,4-tetrahydroisoquinolinyl sulfamic acids (21) . We hypothesized that pharmacological VE-PTP inhibition would activate Tie-2 signaling in ECs independent of Ang-1/Ang-2 ligands, stabilizing tumor vessels and mitigating the negative consequences of tumor vessel instability (20) .
Methods

Cell Lines and Cell Culture
The sources of human umbilical vein endothelial cells (HUVECs), human microvascular endothelial cells (HMVECs), 4T1, and E0771 cells, the derivation of MMTV-PyVT tumor cells, and the culture conditions of these cells are described in the Supplementary Materials (available online). In short, ECs were cultured in endothelial growth medium (Lonza, Allendale, NJ), and tumor cells were cultured in Dulbecco's modified Eagle's medium with 10% serum and additional growth supplements as per standard protocols.
Short Hairpin RNA (shRNA) and Lentiviral Delivery
For silencing of Tie-2 in HUVECs, we screened a lentiviral target gene set to TEK (synonym: TIE2, accessions NM_000459, AB208796, BC035514, and L06139; Thermo Scientific, Logan, UT). Lentiviral particles were generated by cotransfection of pLKO.1-shTEK, pVSVG, and pΔVPR into HEK293T cells using the Fugene6 protocol (Roche, Indianapolis, IN). Silencing efficiency of TEK in ECs was determined by Western blotting, and clone ID TRCN0000000415 was chosen. Lentiviral particles containing a scrambled shRNA sequence were purchased from Sigma (St Louis, MO). Low passage HUVECs were transduced for 24 hours and then subjected to antibiotic selection with 2 mcg/mL puromycin for 24 to 48 hours.
Animal Use
All animal procedures were performed following the guidelines of Public Health Service Policy on Humane Care of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the Massachusetts General Hospital, Boston, Massachusetts. Zebrafish and mice were bred and maintained in the MGH Cardiovascular Research Center and in a gnotobiotic animal facility in the Edwin L. Steele Laboratory (suppliers listed in Supplementary Materials, available online), respectively.
Zebrafish Embryonic Angiogenesis Assays
Flk-1:GFP (GFP, green fluorescent protein) transgenic zebrafish were obtained from the MGH Cardiovascular Research Center (Charlestown, MA). Fertilized eggs were incubated in E3 fish water with or without AKB-9778. Embryos were examined under an epifluorescent stereomicroscope at 48 hours postfertilization to manually count the number of intersegmental vessels reaching the dorsal longitudinal anastomotic vessel.
Zebrafish Xenograft Assays
Zebrafish tumor xenografts were established using modifications of a previously published protocol (22) (details in Supplementary Methods, available online). Tumor neovascularization was examined by confocal microscopy; axial sections were obtained through the entire tumor mass, and five sections were analyzed per embryo. Neovascularization was quantified by the ratio of GFP-positive area (ECs) to dsRed-positive area (tumor mass) using ImageJ software (National Institutes of Health, Bethesda, MD).
In Vitro Detection of Nitric Oxide Production in HUVECs
Using DAF-2 DA In vitro detection of EC nitric oxide production was performed through a modified version of previously published protocols (23) using the DAF-2 DA fluorescent indicator. Details are provided in the Supplementary Methods (available online).
Mouse Tumor Models C57BL6/J, FVB/N, and FVB/N-Tg(MMTV-PyVT)634Mul/J mice were originally obtained from Jackson Laboratories (Bar Harbor, ME), and Nos3 -/-mice were obtained from Dr Paul L. Huang (Massachusetts General Hospital, Boston, MA). Experiments were all performed on female mice aged 6 to 8 weeks. Methods for tumor cell injection are detailed in the Supplementary Materials (available online). The number of animals in each experimental group is detailed in the figure legends.
Drug Treatment of Mice
AKB-9778 dissolved in 5% dextrose was injected at 40 mg/kg subcutaneously every 12 hours, except where otherwise specified. Control vehicle was the same volume of 5% dextrose. Doxorubicin was given at 2.5 mg/kg by intraperitoneal injection every 72 hours.
Metastasis Assays
To count and measure macroscopic metastases, lungs were immersed in Bouin's solution (Sigma) for 24 hours and examined under a ×4 stereomicroscope. To examine metastases histologically, we resected lungs at the timepoints described, fixed tissue in 4% formaldehyde, and prepared 5-μm paraffin-embedded sections at 100-μm intervals throughout all lobes of all lungs. These were stained with hematoxylin and eosin, and metastases were counted by a trained pathologist. Metastasis area was determined using ImageJ software (National Institutes of Health). For experimental metastasis assays, 4T1 (1 × 10 6 ), E0771 (5 × 10 5 ), or MMTV-PyVT (5 × 10 5 ) cells were injected into the tail vein, and treatment commenced 12 hours later. Lung tissue was collected after fixation by intratracheal instillation of 4% paraformaldehyde (after 8 days' treatment for 4T1 and 5 days' treatment for E0771 and MMTVPyVT). Three representative 5-μm sections (at least 100 μm apart) through each lobe of each lung were stained with hematoxylin and eosin and analyzed by a trained pathologist. Each tumor focus was graded as intra-or extravascular, and the number of cell nuclei visible at ×400 magnification in each focus was counted as a marker of tumor size.
Measurement of Tumor Hypoxia and Perfusion
Tumor hypoxia and perfusion were measured as previously described (12) .
Radiotherapy
Tumor-bearing mice were anesthetized with ketamine and xylazine by intraperitoneal injection. Mice were secured in the supine position on a supportive platform using adhesive tape. A 6-mm thick 15-mm lead collimator was placed over the mammary fat pad tumor, and the mouse was placed into the irradiator (XRAD 320; Precision X-Ray, North Branford, CT). Radiation was directed at 3.52 Gy/min to a total of 20 Gy.
Statistical Analysis
Statistical analysis was performed using the unpaired t test. The χ 2 and Fisher exact tests were used as indicated to compare the relative distribution of metastatic events (by size or location). Repeated measures one-way analysis of variance was used for the analysis of primary tumor growth curves. Survival analysis was performed using the log-rank (Mantel-Cox) test. All statistical tests were two-sided. Differences were considered statistically significant at a P value less than .05.
See additional Materials and Methods in the Supplementary Materials (available online).
results
Effect of AKB-9778, a VE-PTP Inhibitor, on Endothelial Tie-2 Signaling
In keeping with its activity as a VE-PTP inhibitor, AKB-9778 invoked rapid phosphorylation of tyrosine residues on the Tie-2 kinase in two EC lines ( Figure 1A ; Supplementary Figure 1A , available online), in turn activating known downstream pathways AKT and endothelial nitric oxide synthase (eNOS), the latter at the stimulatory Ser1177 residue ( Figure 1B ; Supplementary Figure 1B , available online). These effects were diminished when Tie-2 expression was knocked down in ECs using a TIE2-shRNA construct, establishing target specificity of AKB-9778 ( Figure 1C ; Supplementary Figure 1C , available online). In vivo, a single dose of AKB-9778 led to rapid phosphorylation of Tie-2 tyrosine residues in murine lung and mammary carcinoma tissue (Figure 1 , D and E). Importantly, the activation of Tie-2 signaling in ECs in vitro was seen in the absence of Ang-1 and even in the presence of exogenous Ang-2 ( Figure 1F ).
Effect of AKB-9778 on EC Junctional Protein
The EC/EC adhesion molecule VE-cadherin has also been reported as a potential substrate for VE-PTP (either directly or through plakoglobin) (24) . We found that although VE-PTP inhibition with AKB-9778 induced tyrosine phosphorylation of plakoglobin and VE-cadherin (Supplementary Figure 1 , D and E, available online), the amount of VE-cadherin at the EC membrane was unchanged (Supplementary Figure 1G , available online). Moreover, there was no statistically significant indirect serine phosphorylation of VE-cadherin (a key determinant of its internalization) (Supplementary Figure 1F , available online).
Impact of VE-PTP Inhibition on Embryonic Angiogenesis
The VE-PTP -/-mouse is embryonically lethal because of defects in angiogenesis (25, 26) . Because the VE-PTP domains of Danio rerio and Mus musculus have high sequence homology, we evaluated the effects of AKB-9778 on embryonic vessels in Flk1:GFP zebrafish. We found specific effects on angiogenesis: intersegmental vessels appeared tortuous with reduced sprouting and at higher doses failed to reach the dorsal longitudinal anastomotic vessel at 48 hours postfertilization ( Figure 2 , A and B) (P < .01 by χ 2 test for Figure 2B ). In addition, AKB-9778 reduced angiogenic sprouting into carcinoma xenografts growing in the avascular perivitelline space of zebrafish embryos (P < .01 by twosided t test) ( 
Effect of VE-PTP Inhibition on Early-Stage Primary Tumor Vasculature and Growth
We next examined the effects of VE-PTP inhibition on pathological angiogenesis in breast cancer models in adult mice. First, we implanted 4T1 and E0771 murine mammary carcinoma cells in the mammary fat pad and initiated AKB-9778 treatment 24 hours later. AKB-9778 delayed the early phase of tumor growth in both models (Supplementary Figure 3 , A-C, available online) but not the later phase of tumor growth. VE-PTP gene expression was not detectable in either tumor cell line by reverse-transcription polymerase chain reaction (not shown), and AKB-9778 had virtually no cytotoxic effects on these cells in vitro (median inhibitory concentration > 300 μM). Histologic examination of 4T1 tumors during this early phase of growth (tumor diameter < 1 mm) showed that AKB-9778 promoted vascular maturity, enhancing PVC coverage and proximity between PVCs and ECs (Supplementary Figure 3 , D-F, available online).
Effect of VE-PTP Inhibition on the Growth of Spontaneous Micrometastases
To specifically study the effects of VE-PTP inhibition on metastasis, we used a model of spontaneous 4T1 mammary carcinoma metastasis and treated mice with AKB-9778 only after resecting primary tumors (ie, in an adjuvant therapy setting) ( Figure 3A ). AKB-9778 treated mice had a reduction in the number and size of macroscopic metastatic nodules in the lungs (control mean = 21.8 lung nodules per mouse, 95% confidence interval [CI] = 11.3 to 32.3; AKB-9778 mean = 8.6 lung nodules per mouse, 95% CI = 4.6 to 12.6; P = 0.03 by two-sided t test) and throughout the rest of the body, including liver, lymph nodes, and bones ( Figure 3 , B-E) (control mean = 26.7 total metastatic nodules per mouse, 95% CI = 15.5 to 37.9; AKB-9778 mean = 11.6 lung nodules per mouse, 95% CI = 6.1 to 17.1; P = .03 by two-sided t test). Detailed histologic assessment revealed that this effect was due to a delay in the growth but not in the number of metastases (Supplementary Figure 4 , A-C, available online). These results show that VE-PTP inhibition delays the progression of micrometastases into macroscopic metastatic nodules.
Effect of VE-PTP Inhibition on Metastatic Tumor Cell Extravasation Into the Lungs
To determine if this effect of AKB-9778 on metastasis growth was specifically due to improved vessel stabilization by Tie-2 activation, we used an experimental metastasis model. 4T1 cells, known to have an extended intravascular growth phase after homing to the lungs, were intravenously injected, and AKB-9778 treatment commenced 24 hours later. After 8 days, the lungs of AKB-9778-treated mice showed statistically significantly smaller micrometastases (Supplementary Figure 5A , available online) (P < .01 by two-sided t test). Histologically, AKB-9778-treated mice showed clumps of metastatic cells lodged within alveolar vessels that failed to breach the vascular basement membrane and enter the lung parenchyma (Figure 4 , A-C) (statistically A) Tie-2 tyrosine phosphorylation in human umbilical vein endothelial cell (HUVEC) lysates after AKB-9778 treatment. B) Levels of phosphorylated AKT (Ser473), total AKT, phosphorylated endothelial nitric oxide synthase (eNOS) (Ser1177), and total eNOS in HUVEC lysates after treatment with AKB-9778 (numbers below blot indicate densitometric ratios as labeled). C) Phosphorylated AKT (Ser473 residue), total AKT, phosphorylated eNOS (Ser1177 residue), and total eNOS levels in HUVEC lysates or TIE2-shRNA HUVEC lysates after exposure in vitro to AKB-9778 (numbers below blot indicate densitometric ratios as labeled). D) Tie-2 tyrosine phosphorylation in murine whole lung lysates 1 hour after intravenous injection of AKB-9778 or control vehicle. E) Tie-2 tyrosine phosphorylation in murine orthotopic 4T1 mammary carcinoma lysates 1 hour after intravenous injection of AKB-9778 or control vehicle. F) Levels of phosphorylated AKT (Ser473), total AKT, phosphorylated eNOS (Ser1177), and total eNOS in HUVEC lysates after 30 minutes of treatment with angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2), and/or AKB-9778. Given the finding that AKB-9778 delays extravasation of metastatic tumor cells into the lungs and slows progression of micrometastases, we asked if adjuvant AKB-9778 therapy in the 4T1 spontaneous metastasis model could improve outcomes beyond a standard cytotoxic therapy. Indeed, there was a strong trend toward improved overall survival from the addition of AKB-9778 to adjuvant doxorubicin chemotherapy from 27.0 to 36.5 days in this model (hazard ratio for overall survival = 0.33, 95% CI = 0.11 to 1.03; P = .05 by Mantel-Cox test) ( Figure 4E ).
Effects of VE-PTP Inhibition on the Structure and Function of Established Primary Tumor Vessels
Next, we examined the effects of VE-PTP inhibition on the vasculature of established primary tumors that would have already passed through the "angiogenic switch" (commencing treatment at tumor diameter 3 mm). In both 4T1 and E0771 breast tumor models, AKB-9778 therapy led to more structurally mature tumor vessels, evidenced by increased PVC coverage ( Figure 5, A 
test). D)
Representative images of lungs visualized after resection in control (upper panels) and AKB-9778 treated (lower panels) mice (scale bars = 10 mm). E) Total number of macroscopically detected metastases (including lung, liver, bone, lymph node, and soft tissue) (*P = .03 by two-sided t test; n = 10 per group). For all panels, error bars represent standard deviation. perivascular cells) (*P = .05 by two-sided t test; n = 6 per group) in E0771 tumors (*P < .01 by two-sided t test; n = 6 per group). E) Enhanced vascular pericyte coverage in AKB-9778-treated tumors (right panel) compared with control-treated tumors (left panel) (red: CD31; green: NG2; blue: DAPI). F-G) Vessel diameter in control vs AKB-9778-treated 4T1 (F) and E0771 (G) tumors (F: *P < .01 by two-sided t test, n = 6 per group; G: *P < .01 by two-sided t test, n = 6 per group). H-I) Vessel density in control vs AKB-9778-treated 4T1 (H) and E0771 (I) tumors (H: *P = .05 by two-sided t test, n = 6 per group; I: *P = .05 by two-sided t test, n = 6 per group). Error bars represent standard deviation for all panels.
AKB-9778 vessel diameter mean = 11.7 μM, 95% CI = 11.2 to 12.2 μM, P = .003 by two-sided t-test; in E0771, control vessel diameter mean = 10.5 μM, 95% CI = 10.4 to 10.7 μM, and AKB-9778 vessel diameter mean = 11.7 μM, 95% CI = 11.2 to 12.1 μM, P < .01 by two-sided t test). Consistent with our in vitro data, total VE-cadherin levels in tumor ECs were unchanged after 9 days of AKB-9778 therapy (Supplementary Figure 6A, available online) .
We next assessed the function of vessels in established primary tumors after treatment with AKB-9778. First, AKB-9778 reduced tumor microvascular permeability in keeping with Tie-2 activation ( Figure 6 , A and B) (mean increase in permeability from baseline to day 4 of treatment was 182% for control [95% CI = 85% to 280%] and 13% for AKB-9778 [95% CI = −4% to 30%); P = .03 by two-sided t test). In addition, overall tumor perfusion was increased in both 4T1 and E0771 tumors after AKB-978 therapy ( Given the observed reduction in hypoxia, we then studied the effect of AKB-9778 pretreatment on the efficacy of tumor radiotherapy. Pretreating orthotopic mammary 4T1 tumors with AKB-9778 led to a modestly enhanced growth delay from subsequent radiotherapy (time to tumor doubling in volume after radiotherapy prolonged by approximately 2.5 days; P <.01 by analysis of variance when comparing radiotherapy alone and AKB plus radiotherapy groups). Given that AKB-9778 monotherapy had no effect on tumor growth in this setting, these data indicate tumor radiosensitization by AKB-9778 pretreatment ( Figure 6J ).
Systemic Effects of AKB-9778 Therapy
We next examined the effects of AKB-9778 therapy on the structure and function of nontumor vessels. In healthy non-tumorbearing mice, AKB-9778 reduced cutaneous vessel permeability as assessed by the Miles assay and increased cutaneous vessel diameter after 48 hours of treatment, consistent with Tie-2 activation (Supplementary Figure 8, A and B, available online) . Despite the observed increase in vessel diameter, there was no change in systemic blood pressure after AKB-9778 treatment of tumor-bearing mice (Supplementary Figure 8C , available online).
Role of eNOS in Mediating VE-PTP-induced Tumor Vascular Alterations
We have previously found that recreating nitric oxide gradients around the tumor vascular endothelium mediates angiogenesis and vessel maturation, improving tissue perfusion and oxygenation (29, 30) . Given our finding that AKB-9778 increases phosphorylation of EC eNOS at the Ser1177 residue ( Figure 1B) , we next examined whether the improved perfusion seen after VE-PTP inhibition in established primary tumors is due to heightened eNOS activity. Importantly, neither AKB-9778 nor recombinant Ang-1 enhanced phosphorylation at the inhibitory Thr495 eNOS residue in ECs (Supplementary Figure 9, available online) . Consistent with this, AKB-9778 induced a marked increase in EC nitric oxide production in vitro that was abolished by an NOS inhibitor ( Figure 7, A  and B) . When administered to eNOS-deficient (Nos3 -/-) mice bearing established orthotopic E0771 breast carcinomas, AKB-9778 therapy had no effect on tumor growth, which is consistent with previous experiments in this late treatment setting in wild-type mice ( Figure 7C ). Unlike wild-type mice tumors, however, we did not observe an increase in vessel density or diameter by AKB-9778 treatment in Nos3 -/-mice, suggesting that the effects of VE-PTP inhibitor are at least in part mediated by eNOS (Figure 7 , D and E) (29) .
Discussion
In this study, we show that pharmacological inhibition of the VE-PTP domain stabilizes tumor vessels through activation of the EC Tie-2 kinase. Using AKB-9778, a novel, first-in-class VE-PTP inhibitor, we showed direct benefits of VE-PTP inhibition in several stages of tumor progression including metastasis.
As a VE-PTP inhibitor, AKB-9778's capacity to activate the Tie-2 kinase is in keeping with previous work demonstrating that inhibition of VE-PTP expression by antibodies, small interfering RNA, or gene disruption triggers Tie-2 tyrosine phosphorylation in ECs (20) . Furthermore, the angiogenic defects observed in VE-PTP -/-mouse embryos (attributed to Tie-2 hyperactivation) are recapitulated by AKB-9778 in our zebrafish embryonic angiogenesis assays (25, 26) .
Importantly, the extracellular domain of VE-PTP associates with VE-cadherin. Nottebaum et al. have shown that VE-PTP might be important in maintaining EC junctional integrity through a mechanism requiring plakoglobin and VE-cadherin (24). Although we observed increased tyrosine phosphorylation of both plakoglobin and VE-cadherin in ECs after AKB-9778 exposure, we found no change in VE-cadherin subcellular localization in vitro or in total VE-cadherin levels in tumor ECs in vivo after prolonged AKB-9778 treatment. Moreover, the observed reductions in vascular permeability are consistent with Tie-2 activation rather than impaired EC junctional integrity. Collectively, these data show that the effects of pharmacological VE-PTP domain inhibition are mediated primarily through increased Tie-2 kinase activity.
The ligand-independent activity of AKB-9778 is an attractive property and is relevant when comparing anti-Ang-2 therapies to VE-PTP inhibition. First, inter-and intratumor levels of Ang-2 are highly variable (31) , and anti-Ang-2 strategies can only be effective in tumors and regions that express sufficient levels of Ang-2. In contrast, we show that VE-PTP inhibition activates Tie-2 regardless of ligand context. Second, because tumors typically express higher levels of Ang-2 than Ang-1 (15), Ang-2 blockade may not necessarily lead to Tie-2 activation in tumor ECs. In contrast, VE-PTP inhibition consistently activates Tie-2 and its downstream effector pathways, even in the presence of Ang-2.
Early in primary tumor development, cancer cells co-opt host vessels that then upregulate production of Ang-2 (6) and VE-PTP (26) , presumably leading to Tie-2 deactivation, vessel destabilization, and sprouting angiogenesis (6). Our observation that JNCI | Articles 1197 jnci.oxfordjournals.org by pimonidazole staining in control vs AKB-9778-treated 4T1 (G) and E0771 (H) tumors (G: *P = .05 by two-sided t test, n = 10-13 per group; H: *P = .04 by two-sided t test, n = 9-10 per group). For (A) and (B), data were obtained after 72 hours of treatment, and for (C-H), treatment was commenced at tumor diameter of 3 mm and continued for 10 days. I) Intravital optical frequency domain imaging of 4T1 mammary carcinomas at baseline (day 0, diameter 2-3 mm) and after 4 days of treatment with AKB-9778 or control vehicle. Images show perfused vessels only. Scale bars represent 4 mm. J) 4T1 tumor growth curves from combined AKB-9778 and radiotherapy. Treatment was begun at diameter 3 mm, and radiotherapy given 1 week later (*P < .01 comparing green and pink lines by analysis of variance; n = 7 per group). For all panels, error bars represent standard deviation.
inhibition of the VE-PTP during this time stabilizes host vessels and delays the early phase of primary tumor growth is consistent with the results seen when growing tumors in Ang-2-deficient mice (32) .
The early phase of tumor growth is most clinically relevant to the progression of micrometastases to macroscopic tumors. Metastatic cells that home to distant organs subsequently adhere to ECs that in turn upregulate Ang-2 (6). The resultant vessel destabilization facilitates extravasation subsequent and micrometastatic colonization of cells into distant organs (33, 34) . Here, we show that Tie-2 activation through VE-PTP inhibition constrains metastatic tumor cells to the distant organ's intravascular compartment, hence slowing metastatic progression. Previous studies have shown a reduction in spontaneous metastasis using Ang-2 blockade (14, 15) . In those models, however, anti-Ang-2 monotherapy or anti-Ang-2/ VEGF double therapy statistically significantly delayed primary tumor growth, which could in itself delay metastasis. By using a spontaneous metastasis model where therapy was only begun after resection of the primary tumor, we show that VE-PTP inhibition delays progression of existing micrometastases to macrometastases and prolongs mouse survival. Furthermore, our experimental metastasis models confirm inhibition of the extravasation step of the metastatic cascade after VE-PTP inhibition. In prior preclinical studies, it has been suggested that surgical removal of a primary tumor may remove an angio-inhibitory stimulus upon micrometastases, promoting their progression through neovascularization (35) . Therefore, further studies examining the role of perioperative AKB-9778 therapy are warranted.
We also observed structural and functional normalization of vessels after AKB-9778 therapy of established tumor vessels. Our -/-mice (P = .40 by two-sided t test; n = 5 per group). E) Vessel density in E0771 orthotopic mammary carcinomas treated with AKB-9778 or control vehicle in NOS3 -/-mice (P = .77 by two-sided t test; n = 5 per group). For all panels, error bars represent standard deviation.
JNCI | Articles 1199 jnci.oxfordjournals.org results are in part supported by a previous study showing that VE-PTP gene silencing in embryonic stem cell-derived tumors increases vessel diameter (27) . As we have previously shown (12) , anatomically small differences in vascular structure (such as increased PVC-EC proximity and increased vessel diameter) can have profound effects of normalizing vascular function. The accompanying increase in tumor perfusion and reduction in hypoxia are clinically relevant: reduced tumor perfusion and tumor hypoxia are known determinants of aggressive tumor behavior, insensitivity to chemo-and radiotherapy, and a poor prognosis (9, 36, 37) . By activating Tie-2 signaling, VE-PTP inhibition reduces hypoxia and improves radiotherapy efficacy. These effects differ from those previously observed from anti-Ang-2 therapies of solid tumors, which characteristically result in narrowed vessels with an increase in tumor hypoxia (15, 17) . This may relate to the previously discussed differences between anti-Ang-2 therapy and VE-PTP inhibition on the state of Tie-2 activity. Although the goal of sustained improvement in perfusion and oxygenation has previously been realized through the use of genetic mouse models (3, 38) , gene targeting (4), and cytokine therapy (39), we present here a novel approach to achieve similar effects using a low molecular weight pharmacological agent.
Our observation that Tie-2 activation by VE-PTP inhibition increases eNOS phosphorylation at its stimulatory Ser1177 residue with no accompanying increase in Thr495 phosphorylation stands in contrast to a previous report (40) but is consistent with eNOS biology, where counter-regulatory residues are typically phosphorylated/dephosphorylated in a manner that yields a unidirectional effect on enzyme activity. The resultant increase in EC nitric oxide production is also in keeping with these findings. We have previously demonstrated that concentrating intratumoral nitric oxide around the endothelial compartment normalizes tumor vessel structure and function, improving perfusion and reducing hypoxia (29, 30) , and here we show that eNOS mediates vessel density and diameter increases by AKB-9778. Further studies are required to fully understand the involvement of eNOS in AKB-9778's effects on blood vessels, tumor progression, and dissemination.
There are, however, a number of limitations in our study. First, further work is needed to validate the importance of VE-PTP in human solid tumors. Second, it will be important to see whether results similar to what we saw in mammary tumors are reproduced in models of other tumor types. Third, further studies in spontaneously arising tumors, which may more faithfully replicate the tumor vessel phenotype, are warranted because the majority of our current data comes from models using implantable tumors from murine cell lines. Finally, we acknowledge that the understanding of VE-PTP biology and targets remains an emerging field, and the vascular effects should be evaluated as new potential targets for the phosphatase are discovered.
In summary, we propose sustained Tie-2 activation by VE-PTP inhibition as a novel approach to tumor vascular normalization (Figure 8 ). Unlike the majority of small molecule-targeted therapies that inhibit tyrosine kinases, AKB-9778 works to increase Tie-2 kinase activity and hence stabilizes vessels and normalizes their function. VE-PTP inhibition has not been reported in any disease model before, but first-in-human dose-finding studies with AKB-9778 are now complete (41) . Our data provide novel biological insights into the role of VE-PTP in tumor initiation, progression, metastasis, and treatment. 
